New Strategies Needed As China Shakes Up Drug Class Rules?

This article was originally published in SRA

16 Mar 2016
News

Brian Yang @bhxyang brian.yang@informa.com

Executive Summary

Like a stone being thrown into a pool of calm water, the China Food and Drug Administration released on March 9 "Document 51, Reform Plans for Chemical Drug Registration", stirring up immediate reactions from the pharma industry¹.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS118584

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS118584

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

New Strategies Needed As China Shakes Up Drug Class Rules?

News

Executive Summary

Related Content

2016 Review: Rapid Change Defines China Regulatory Environment

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert